Vaxcyte Q2 EPS $(1.97) Beats $(2.22) Estimate
Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.97) per share which beat the analyst consensus estimate of $(2.22) by 11.26 percent. This is a 61.48 percent decrease over losses of $(1.22) per share from the same
Vaxcyte lost less money than experts expected, which is good news for a company still growing. When a company that's not yet profitable loses less than people thought it would, it means the business might be getting stronger.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.